Your session is about to expire
← Back to Search
Durvalumab After Radiation for Stage 3 Lung Cancer (DUART Trial)
DUART Trial Summary
This trial is testing a new cancer drug to see if it is effective in treating patients with Stage III lung cancer who are not eligible for chemotherapy. The trial will enroll patients into two groups depending on the dose of radiation therapy they have received.
- Non-Small Cell Lung Cancer
DUART Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 80 Patients • NCT03015129DUART Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You currently have a contagious infection like tuberculosis, hepatitis B, hepatitis C, or HIV.You received a live vaccine in the month before starting durvalumab.You have a history of cancer spreading to the membranes surrounding the brain and spinal cord.You have had another type of cancer in the past.You have a history of ongoing immune system problems.You are still experiencing side effects from previous cancer treatment that are rated as moderate or severe.You have received an organ from someone else in the past.You have a specific type of lung cancer that is at an advanced stage and cannot be removed with surgery.You have not been treated with immune-based therapy before.You are expected to live for more than 12 weeks.You have received a specific amount of radiation treatment within a certain range.You have taken medication that weakens your immune system within 14 days before starting the durvalumab treatment.You currently have or have had inflammation in your intestines.You have a type of lung cancer that is a combination of small cell and non-small cell types.You have advanced lung cancer that has gotten worse after radiation treatment.You don't want to receive chemotherapy, even if your doctor recommends it.You have a good ability to perform daily activities and take care of yourself.You have not experienced worsening of the condition after receiving radiation therapy, as determined by the doctor's assessment.
- Group 1: Cohort A
- Group 2: Cohort B
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what purposes is Durvalumab commonly prescribed?
"Durvalumab is commonly used to treat advanced cases of stage III non-small cell lung cancer. This medication has also proven useful in treating metastatic ureter urothelial carcinoma and other less common conditions."
What are the eligibility criteria for participation in this clinical trial?
"This clinical trial is admitting 102 individuals with carcinoma, non-small cell lung cancer. The acceptable age range for participants is 18 to 130 years of age. Notably, prospective patients must meet the following qualifications: World Health Organization/ECOG performance status ≤2., Previous radiation therapy dose between 40 and 66 Gy (standard or hypofractionated BED)., No progression from prior treatment according to Investigator assessed RECIST 1.1 criteria regarding measurability of lesions ., Age ≥18 at study entry., Ineligible for chemotherapy as per investigator assessment., Not having been previously exposed to immune-mediated therapies such as anti-CTLA"
How many individuals have volunteered for this clinical investigation?
"Currently, this clinical study is not searching for new enrollees. It was originally posted on November 26th 2020 and underwent its last edits on November 23rd 2022. For those seeking other opportunities, 1949 trials are actively recruiting patients with carcinoma non-small cell lung cancer and 333 studies need volunteers to partake in Durvalumab research."
To what extent are hospitals participating in this research endeavor?
"At the time of writing, 4 centres are recruiting participants for this trial. These sites can be found in Tampa, Tucson and Tacoma as well as several other locations. It is recommended that you select a clinic closest to your residence so that travel demands remain minimal if you decide to join."
Does this research endeavor have an age requirement of 18 years or older?
"According to the regulatory requirements of this clinical trial, eligible participants must be aged 18 and no older than 130 years."
To what degree is Durvalumab a danger to human health?
"Durvalumab's safety was rated a 2 since it is in the second phase of clinical trials and has evidence for its safe use, yet there are no studies that verify its efficacy."
Are there any past experiments involving Durvalumab to reference?
"Durvalumab was first trialed in 2010 at City of Hope and since then, 106 scientific studies have concluded. At the moment, 333 experiments are ongoing with a large number based out of Tampa, Florida."
Is the trial currently offering enrollment opportunities?
"As indicated on clinicaltrials.gov, this particular research study is no longer accepting patients for enrollment. The trial was first listed in November 2020 and updated last month; yet there are still 2282 other medical trials that need volunteers at the present moment."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger